1. Stanozolol in the Treatment of Pityriasis Rubra Pilaris
- Author
-
Lawrence Barfield, Gary L. Heller, L. Boyd Savoy, George P. Pavlidakey, Ken Hashimoto, and Davide Iacobelli
- Subjects
Vitamin ,Pathology ,medicine.medical_specialty ,business.industry ,Vitamin E ,medicine.medical_treatment ,Erythroderma ,Dermatology ,General Medicine ,medicine.disease ,Ascorbic acid ,Keratitis ,chemistry.chemical_compound ,Palmoplantar keratoderma ,Hair loss ,chemistry ,medicine ,Pityriasis rubra pilaris ,business - Abstract
Pityriasis rubra pilaris (PRP) is a rare papulosquamous disease characterized by erythroderma, acuminate follicular papules, with so-called islands of sparing, follicular hyperkeratosis, palmoplantar keratoderma and occasional lymphadenopathy, hair loss, mucosal lesions (white or blue lines or erythematous lesions transversed by white streaks), and eye lesions (corneal opacities, conjunctivitis, keratitis). Pityriasis rubra pilaris can be widespread and very distressing to the patient, because limitation of motion and painful fissuring of palmar and plantar surfaces can occur. Among the many treatment modalities that have been used are vitamin A alone1or in combination with vitamin E,2topical aminonicotinamide,3azathioprine,4methotrexate,5isotretinoin,6etretinate,7PUVA,7and systemic steroids.8Anecdotal reports indicate that ascorbic acid or penicillin might also be of benefit. Lamar and Gaethe,8in their review of PRP, documented the effects of old remedies, such as arsenic, foreign protein injections, pilocarpine, pituitary extract, carotene
- Published
- 1985